{
    "clinical_study": {
        "@rank": "28258", 
        "arm_group": {
            "arm_group_label": "Consta Sustenna switching", 
            "description": "The patients group who switched to paliperidone palmitate from risperidone long acting injection"
        }, 
        "brief_summary": {
            "textblock": "The aim of this study is observation of effectiveness and side effect of patients with\n      schizophrenia who will switch the antipsychotics from risperidone long acting injection to\n      paliperidone palmitate."
        }, 
        "brief_title": "Switching From Consta\u00ae to Sustenna\u00ae in Patients With Schizophrenia", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "detailed_description": {
            "textblock": "In this study, investigators are going to enroll the patients who will switch the\n      risperidone long acting injection to paliperidone palmitate. And investigators will examine\n      the effectiveness and side effect of paliperidone palmitate. In addition, effectiveness and\n      side effect related variables will be studied."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: 18 ~ 65\n\n          -  Patient with schizophrenia according to DSM-IV criteria\n\n          -  Patient have signed on the informed consent, and well understood the objective and\n             procedure of this study.\n\n          -  Maintenance therapy more than 6 months with Risperidone Long Acting Injection\n             monotherapy or other with concomitant antipsychotics, and stable dose of Risperidone\n             Long Acting Injection was maintained 8 weeks more. The stable dose of other\n             antipsychotics has been maintained 8 months and more.\n\n          -  Patient wants to switch antipsychotics to Paliperidone Palmitate.\n\n          -  PANSS total score \u2264 80\n\n          -  Each score of conceptual disorganization(P2), hallucinatory behavior(P3),\n             Suspiciousness/persecution(P6), unusual thought content(G9)in PANSS \u2264 4\n\n          -  Competent patient who is manage to answer the questionnaires.\n\n          -  In case of female at child-bearing age, consent to use appropriate contraceptive\n             methods(oral pill, contraceptive injection, intrauterine device, double barrier\n             method and contraceptive patch) during entire duration of this study.\n\n        Exclusion Criteria:\n\n          -  No history of antipsychotics use.\n\n          -  Past history of NMS.\n\n          -  Allergy or hypersensitivity to Risperidone or Paliperidone ER.\n\n          -  Concomitant antipsychotics was oral Risperidone or Paliperidone ER.\n\n          -  Initiating or dose-changing of SSRI, MAOI, TCA within 2 months(maintenance is allowed\n             if those have been stable for at least 30days prior to study entry and would not be\n             any dose changes during the study)\n\n          -  Initiating of Lithium, Valproic acid, Carbamazepine, Topiramate, Lamotrigine or other\n             mood stabilizer within 2months (maintenance is allowed).\n\n          -  Patient who is supposed to be impossible to participate to this study due to clinical\n             risk of suicide or aggressive behavior based on clinician's opinion.\n\n          -  Current substance dependence(DSM-IV) or past history of dependence (more than\n             6months)\n\n          -  Significant biochemical or hematological abnormality or abnormal finding of\n             urinalysis, based on clinician's opinion.\n\n          -  History of cardiac disease which predispose to QT prolongation(sick sinus, complete\n             AV block, CHF, ventricular tachycardia, hypokalemia or hypocalcemia) or current\n             medication of QT prolonging drugs\n\n          -  Pregnant or breast-feeding female patient.\n\n          -  History of participating to other investigational drug trial within 1month prior to\n             screening.\n\n          -  Investigator or employee at clinical trial center, personnel related to investigator\n             or trial center on this or other study, or family of employee or investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with schizophrenia who would be switched to Paliperidone Palmitate from\n        Risperidone Long Acting Injection"
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01698216", 
            "org_study_id": "Consta_Sustenna"
        }, 
        "intervention_browse": {
            "mesh_term": "9-hydroxy-risperidone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Paliperidone", 
            "Palmitate", 
            "switching", 
            "schizophrenia", 
            "subjective well-being"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "location": {
            "contact": {
                "email": "hjlee.np@gmail.com", 
                "last_name": "Hyun Jeong Lee, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "investigator": {
                "last_name": "Yong Min Ahn, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Switching From Risperidone Long Acting Injection (Consta\u00ae) to Paliperidone Palmitate (Sustenna\u00ae) in Patients With Schizophrenia and Its Influence on Subjective Well-Being: A Prospective Observational Study", 
        "overall_contact": {
            "email": "hjlee.np@gmail.com", 
            "last_name": "Hyun Jeong Lee, MD"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Yong Min Ahn, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Subjective Well-being Under Neuroleptic Treatment (SWN)", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline in SWN score at 108 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698216"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Yong Min Ahn", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Korean Drug Attitude Inventory-10", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline in score at 108 weeks"
            }, 
            {
                "measure": "Positive and Negative Syndrome Scale", 
                "safety_issue": "No", 
                "time_frame": "0,4,8,16,24,36,48,60,72,84,96,108 week"
            }, 
            {
                "measure": "Clinical Global Impression-Severity, Improvement", 
                "safety_issue": "No", 
                "time_frame": "0,4,8,16,24,36,48,60,72,84,96,108 week"
            }, 
            {
                "measure": "Personal and Social Performance Scale", 
                "safety_issue": "No", 
                "time_frame": "0,4,8,16,24,36,48,60,72,84,96,108 week"
            }, 
            {
                "measure": "Symptom Check List-90-Revised", 
                "safety_issue": "No", 
                "time_frame": "0,4,8,16,24,36,48,60,72,84,96,108 week"
            }, 
            {
                "measure": "Drug-Induced ExtraPyramidal Symptoms Scale", 
                "safety_issue": "Yes", 
                "time_frame": "0,4,8,16,24,36,48,60,72,84,96,108 week"
            }, 
            {
                "measure": "Liverpool University Neuroleptic Side Effect Rating Scale", 
                "safety_issue": "Yes", 
                "time_frame": "0,4,8,16,24,36,48,60,72,84,96,108 week"
            }, 
            {
                "description": "injection site pain", 
                "measure": "Visual Analog Scale", 
                "safety_issue": "Yes", 
                "time_frame": "0,4,8,16,24,36,48,60,72,84,96,108 week"
            }, 
            {
                "description": "electrocardiogram", 
                "measure": "ECG", 
                "safety_issue": "Yes", 
                "time_frame": "8, 24, 48, 72, 108 week"
            }, 
            {
                "measure": "blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "0,4,8,16,24,48,72,108 week"
            }, 
            {
                "measure": "Body weight", 
                "safety_issue": "Yes", 
                "time_frame": "0,4,8,16,24,48,72,108 week"
            }, 
            {
                "measure": "waist circumference", 
                "safety_issue": "Yes", 
                "time_frame": "0,4,8,16,24,48,72,108 week"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}